Brief: Bellerophon Therapeutics Announces First Patient Treated With Inopulse Inhaled Nitric Oxide Therapy For Covid-19
30/03/2020 15:25
March 30 (Reuters) - Bellerophon Therapeutics Inc BLPH.O :
* BELLEROPHON THERAPEUTICS ANNOUNCES FIRST PATIENT TREATED
WITH
INOPULSE® INHALED NITRIC OXIDE THERAPY FOR COVID-19
Source text for Eikon: ID:nGNX2rYyXn
Further company coverage: BLPH.O
((Briefs@thomsonreuters.com;))
Recent news on Bellerophon Therapeutics
See all newsBrief: Bellerophon Therapeutics Inc On October 12, 2023, Board Of Directors Approved Plan Of Liquidation And Dissolution Of Company
Bellerophon Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Bellerophon Therapeutics Inc expected to post a loss of 42 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Archer-Daniels-Midland, Nucor, Copper miners
U.S. STOCKS ON THE MOVE-Hubbell, Spire Global, FibroGen